Viking Therapeutics (VKTX) Return on Capital Employed (2016 - 2025)
Historic Return on Capital Employed for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to 0.6%.
- Viking Therapeutics' Return on Capital Employed fell 4400.0% to 0.6% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.6%, marking a year-over-year decrease of 4400.0%. This contributed to the annual value of 0.53% for FY2025, which is 2900.0% down from last year.
- Latest data reveals that Viking Therapeutics reported Return on Capital Employed of 0.6% as of Q4 2025, which was down 4400.0% from 0.36% recorded in Q3 2025.
- Over the past 5 years, Viking Therapeutics' Return on Capital Employed peaked at 0.13% during Q2 2024, and registered a low of 0.6% during Q4 2025.
- For the 5-year period, Viking Therapeutics' Return on Capital Employed averaged around 0.29%, with its median value being 0.26% (2025).
- In the last 5 years, Viking Therapeutics' Return on Capital Employed surged by 3400bps in 2024 and then tumbled by -4400bps in 2025.
- Quarter analysis of 5 years shows Viking Therapeutics' Return on Capital Employed stood at 0.27% in 2021, then plummeted by -81bps to 0.48% in 2022, then soared by 41bps to 0.28% in 2023, then surged by 40bps to 0.17% in 2024, then plummeted by -259bps to 0.6% in 2025.
- Its Return on Capital Employed was 0.6% in Q4 2025, compared to 0.36% in Q3 2025 and 0.26% in Q2 2025.